Assessing the efficacy of molecularly targeted agents by using Kalman filter
暂无分享,去创建一个
Michael L. Bittner | Edward R. Dougherty | Lijun Qian | Xiangfang Li | E. Dougherty | M. Bittner | Xiangfang Li | Lijun Qian
[1] S. Johnston,et al. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. , 2001, The Lancet. Oncology.
[2] Nick Holford,et al. Holford NHG and Sheiner LB “Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin Pharmacokin 6:429–453 (1981)—The Backstory , 2011, The AAPS Journal.
[3] Lillian L. Siu,et al. Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.
[4] Mohinder S. Grewal,et al. Kalman Filtering: Theory and Practice , 1993 .
[5] F. Spyratos,et al. Correlation between MIB‐1 and other proliferation markers , 2002, Cancer.
[6] Elizabeth Fox,et al. Clinical trial design for target-based therapy. , 2002, The oncologist.
[7] F. Balis,et al. Evolution of anticancer drug discovery and the role of cell-based screening. , 2002, Journal of the National Cancer Institute.
[8] R. German. Sintering theory and practice , 1996 .
[9] L. Sheiner,et al. Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.